ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

Novartis has done a little spring cleaning, sweeping a phase 2 osteoarthritis prospect and first-in-human radioconjugate out of its pipeline after assessing evidence on the programs. | Novartis has ...

Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. Shares of NYSE:ABBV traded up $2.54 during trading on Tuesday, hitting $194.88. 2,962,467 shares of the company’s stock ...

Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest ...

It’s worth noting that BMS’ decision to exit the deal comes shortly after AbbVie secured full FDA approval for its FRα-directed ADC candidate – Elahere (mirvetuximab soravtansine ...

AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE® (mirvetuximab soravtansine-gynx) in women with ...

Discover insights from Corcept Therapeutics' Q1 2025 earnings call: revenue growth, relacorilant's FDA review, and its strategic outlook ...

The US Food and Drug Administration has approved a 100-mg liquid formulation vial of thiotepa (Tepylute), according to a press release from its maker, Shorla Oncology. Tepylute is an alkylating ...